🇺🇸 FDA
Pipeline program

Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

67-22 PREcoopERA

Phase 2 small_molecule active

Quick answer

Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé for ER-positive/HER2-negative early breast cancer is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Partner Therapeutics Limited
Indication
ER-positive/HER2-negative early breast cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials